Shinagare Atul B, Somarouthu Bhanusupriya, Guo Hao, Tolaney Sara M, Ramaiya Nikhil H
Department of Imaging, Dana-Farber Cancer Institute, Boston, USA; Department of Radiology, Brigham and Women's Hospital, Boston, USA.
Department of Imaging, Dana-Farber Cancer Institute, Boston, USA; Department of Radiology, Brigham and Women's Hospital, Boston, USA.
Clin Imaging. 2018 Mar-Apr;48:44-47. doi: 10.1016/j.clinimag.2017.09.014. Epub 2017 Sep 28.
To compare performance of RECIST1.1 and Choi criteria in assessment of patients with metastatic triple-negative breast cancer treated with cabozantinib.
Thirty patients with metastatic triple-negative breast cancer enrolled in phase 2 clinical trial received cabozantinib. Clinical benefit rates assessed by prospectively determined RECIST1.1 and retrospectively assessed Choi criteria were compared.
Decreased tumor density (≥15%) at first follow-up was seen in 22/30(73%) patients. CBR was 40% (95%CI:23-59%) by RECIST1.1, and 73% (95%CI:54-88%) by Choi (NPV=100%, 95%CI:63-100%; PPV=55%, 95%CI:32-76%).
Morphologic changes are seen in the majority of patients treated with cabozantinib, making Choi criteria valuable in response assessment.
